Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on March 23, 2017, 10:18:41 am
-
Gilead Sciences’ hepatitis C virus (HCV) treatment Harvoni (ledipasvir/sofosbuvir) appears to work as well in real-world practice as it did in clinical trials.
Publishing their findings in the Journal of Viral Hepatitis, researchers analyzed data from a retrospective cohort study of 1,597 people with genotype 1 of hep C who were treated with Harvoni for 12 weeks in a real-world setting; 76 of them also took ribavirin.
Read more...
https://www.hepmag.com/article/harvonis-success-realworld-treatment-hepatitis-c-mirrors-clinical-trials
-
Good to hear!! Anybody know what this means from the study, and why?
'After adjusting the data for various factors, the researchers found that receiving HCV care at an academic center rather than elsewhere was associated with a 44 percent reduced likelihood of achieving a cure. '
-
Good question, Paul. Was wondering same..
Another real life study by Prime Therpeutics showed even higher SVR12 rates with Harvoni:
https://hepatitisnewstoday.com/2017/03/23/harvoni-cured-97-percent-hepatitis-c-patients-real-world-study/ (https://hepatitisnewstoday.com/2017/03/23/harvoni-cured-97-percent-hepatitis-c-patients-real-world-study/)
-
Yup.. so great to read this. I remember a little earlier on some folks here were decrying the clinical results stating that they thought they were trumped up to market the drugs, and that in the real world, we'd all find out those success numbers were way overstated and that real world results could never approach those in the trials.
I guess they were wrong!
-
Dragonslayer asked:
Good to hear!! Anybody know what this means from the study, and why?
'After adjusting the data for various factors, the researchers found that receiving HCV care at an academic center rather than elsewhere was associated with a 44 percent reduced likelihood of achieving a cure. '
==============================
Was really curious bout the same thing . Found answer in the body of the article itself:
http://onlinelibrary.wiley.com/doi/10.1111/jvh.12611/epdf (http://onlinelibrary.wiley.com/doi/10.1111/jvh.12611/epdf)
Whereas both cirrhosis and thrombocytopenia
were inversely related to SVR12 in univariable analyses, treatment
at an academic centre took priority in the multivariable model
suggesting that it may be a more complete marker of disease status
and portal hypertensive complications than thrombocytopaenia
In other words, patients treated at academic centers tended to have more advanced liver disease. Which in general carries a higher risk for viral relapse. But considering there were only 44 viral relapses in almost 1600 patients, might be hard to generalize much from such a low failure number
-
Good find Elias.. Thanks for that. I guess its almost like saying, 'those patients found in kidney dialysis centers are more likely to die of kidney disease than those who arent'.
-
Pretty similar I guess.
Whats interesting is that this increased likelihood is apart from the cirrhosis itself. So apparently having it dealt with via academic centers was a marker for even more advanced liver disease status.
In this particular study, all patients took it for 12 weeks. In an earlier one comparing real world results to trial studies a strong factor in viral failure was non-adherence to FDA prescribing guidelines such as shorter duration of treatment. E.g: 8 weeks where
12 weeks was recommended. I'm guessing insurance companies played a role in that one. So they ought to be made aware of it. Another factor in relapse in an earlier study was patient non-compliance, such as missing doses. Which somehow isn't showing up in this one. But all-in-all, what might be emerging from such studies is a profile of the risk factors for viral failure